

CITATION REPORT

List of articles citing

Long-term use of sildenafil in the therapeutic management of heart failure

DOI: 10.1016/j.jacc.2007.07.078

Journal of the American College of Cardiology, 2007, 50, 2136-44.

Source: <https://exaly.com/paper-pdf/42407616/citation-report.pdf>

Version: 2024-04-20

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
280	Type 5 phosphodiesterase inhibition in heart failure: the next step. <i>Journal of the American College of Cardiology</i> , 2007 , 50, 2145-7	15.1	14
279	Insights into natriuretic peptides in heart failure: an update. <i>Current Heart Failure Reports</i> , 2008 , 5, 97-104	2.8	10
278	Sildenafil and phosphodiesterase-5 inhibitors for heart failure. <i>Current Heart Failure Reports</i> , 2008 , 5, 110-4	2.8	17
277	Pulmonary hypertension secondary to left ventricular systolic dysfunction: contemporary diagnosis and management. <i>Current Heart Failure Reports</i> , 2008 , 5, 226-32	2.8	11
276	Right-sided heart failure: diagnosis and treatment strategies. 2008 , 10, 329-41		20
275	Modulation of the NO/cGMP pathway reduces the vasoconstriction induced by acellular and PEGylated haemoglobin. 2008 , 1784, 1428-34		5
274	The year in heart failure. <i>Journal of the American College of Cardiology</i> , 2008 , 52, 1671-8	15.1	5
273	Clinical use of phosphodiesterase-5 inhibitors in chronic heart failure. <i>Circulation: Heart Failure</i> , 2008 , 1, 272-80	7.6	43
272	Alveolar gas diffusion abnormalities in heart failure. 2008 , 14, 695-702		79
271	The triad: erectile dysfunction--endothelial dysfunction--cardiovascular disease. 2008 , 14, 3700-14		85
270	Evaluation of endothelial dysfunction: flow-mediated dilation. 2008 , 15, 157-63		70
269	Sustained soluble guanylate cyclase stimulation offsets nitric-oxide synthase inhibition to restore acute cardiac modulation by sildenafil. 2008 , 326, 380-7		48
268	Evolving changes in lung interstitial fluid content after acute myocardial infarction: mechanisms and pathophysiological correlates. 2008 , 294, H1357-64		13
267	Determinants of ventilatory efficiency in heart failure: the role of right ventricular performance and pulmonary vascular tone. <i>Circulation: Heart Failure</i> , 2008 , 1, 227-33	7.6	108
266	Diagnosis and treatment of secondary (non-category 1) pulmonary hypertension. 2008 , 118, 2190-9		83
265	Phosphodiesterase-5 inhibition abolishes neuron apoptosis induced by chronic hypoxia independently of hypoxia-inducible factor-1alpha signaling. 2008 , 233, 1222-30		36
264	The clinical importance of cardiopulmonary exercise testing and aerobic training in patients with heart failure. 2008 , 12,		9

263	The effects of vasodilators in pulmonary hypertension: pulmonary vascular or peripheral vascular?. <i>Circulation: Heart Failure</i> , 2009 , 2, 145-50	7.6	19
262	PDE5 inhibitors in non-urolological conditions. 2009 , 15, 3521-39		24
261	Phosphodiesterase 5 inhibition in heart failure: mechanisms and clinical implications. 2009 , 6, 349-55		25
260	Six-minute walk test and cardiopulmonary exercise testing in patients with chronic heart failure: a comparative analysis on clinical and prognostic insights. <i>Circulation: Heart Failure</i> , 2009 , 2, 549-55	7.6	125
259	Erectile dysfunction and heart failure: the role of phosphodiesterase type 5 inhibitors. 2009 , 21, 149-57		12
258	Cyclic GMP signaling in cardiovascular pathophysiology and therapeutics. 2009 , 122, 216-38		273
257	Pulmonary venous hypertension or pulmonary hypertension due to left heart disease. 2009 , 27, 35-42		6
256	Treating heart failure with sildenafil. 2009 , 15, 181-5		10
255	Cardiovascular effects of phosphodiesterase type 5 inhibitors. 2009 , 6, 658-74		38
254	Is ED still only equal to ED?. 2009 , 55, 794-7; discussion 797-800		1
253	Temas de actualidad en insuficiencia cardiaca. 2009 , 9, 92-100		
252	Phosphodiesterase inhibition in heart failure. <i>Heart Failure Reviews</i> , 2009 , 14, 255-63	5	51
251	Kardiale Kontraktilitätsmodulation bei medikamentös therapierefraktärer Herzinsuffizienz. 2009 , 3, 51-54		
250	Pulmonary hypertension in chronic heart failure. <i>International Journal of Clinical Practice</i> , 2009 , 63, 4-10	2.9	11
249	Combined use of PDE5 inhibitors and nitrates in the treatment of pulmonary arterial hypertension in patients with heart failure. 2009 , 15, 31-4		26
248	Six months of Sildenafil therapy improves heart rate recovery in patients with heart failure. <i>International Journal of Cardiology</i> , 2009 , 136, 341-3	3.2	15
247	Mechanisms of exercise intolerance in patients with hypertrophic cardiomyopathy. 2009 , 158, e27-34		22
246	Sildenafil stops progressive chamber, cellular, and molecular remodeling and improves calcium handling and function in hearts with pre-existing advanced hypertrophy caused by pressure overload. <i>Journal of the American College of Cardiology</i> , 2009 , 53, 207-15	15.1	124

245	Pulmonary hypertension in heart failure with preserved ejection fraction: a community-based study. <i>Journal of the American College of Cardiology</i> , 2009 , 53, 1119-26	15.1	724
244	The role of the pulmonary vasculature in heart failure with preserved ejection fraction. <i>Journal of the American College of Cardiology</i> , 2009 , 53, 1127-9	15.1	7
243	Diagnosis, assessment, and treatment of non-pulmonary arterial hypertension pulmonary hypertension. <i>Journal of the American College of Cardiology</i> , 2009 , 54, S85-S96	15.1	284
242	Transpulmonary B-type natriuretic peptide uptake and cyclic guanosine monophosphate release in heart failure and pulmonary hypertension: the effects of sildenafil. <i>Journal of the American College of Cardiology</i> , 2009 , 54, 595-600	15.1	54
241	Hypertension and heart failure: a dysfunction of systole, diastole or both?. 2009 , 23, 295-306		36
240	cGMP: Generators, Effectors and Therapeutic Implications. <i>Handbook of Experimental Pharmacology</i> , 2009 ,	3.2	13
239	Managing Erectile Dysfunction in Patients With Cardiovascular Diseases: The Efficacy and Safety of Phosphodiesterase-5 Inhibitors. 2009 , 3, 201-211		1
238	[Advances in heart failure]. 2009 , 62 Suppl 1, 92-100		0
237	Hypertension artérielle pulmonaire et cœur gauche. 2009 , 1, 251-253		
236	Invasive hemodynamic assessment in heart failure. <i>Heart Failure Clinics</i> , 2009 , 5, 217-28	3.3	54
235	Phosphodiesterase-5 inhibitors: future perspectives. 2009 , 15, 3540-51		33
234	The impact of pharmacotherapy on the cardiopulmonary exercise test response in patients with heart failure: a mini review. 2009 , 7, 557-69		23
233	Diagnostik und Therapie der pulmonalen Hypertonie. 2010 , 4, 189-207		3
232	Erectile dysfunction as a complication of heart failure. <i>Current Heart Failure Reports</i> , 2010 , 7, 194-201	2.8	9
231	Congestion as a therapeutic target in acute heart failure syndromes. 2010 , 52, 383-92		26
230	Determinants of right ventricular failure in patients admitted with acute left heart failure. 2010 , 16, 243-8		13
229	A respiratory response to the activation of the muscle metaboreflex during concurrent hypercapnia in man. 2010 , 95, 194-201		15
228	Update on the clinical utility of sildenafil in the treatment of pulmonary arterial hypertension. 2010 , 4, 61-70		28

227	The management of dyspnoea in chronic heart failure. 2010 , 4, 63-8		12
226	Endothelium-dependent vasodilation is associated with exercise capacity in smokers and non-smokers. 2010 , 15, 119-25		17
225	[Diagnosis and treatment of pulmonary hypertension: European guidelines 2009]. 2010 , 64, 401-14		15
224	Diagnostik und Therapie der pulmonalen Hypertonie: Europäische Leitlinien 2009. <i>Deutsche Medizinische Wochenschrift</i> , 2010 , 135, e2-e15	0	0
223	[Pulmonary hypertension due to left heart disease: recommendations of the Cologne Consensus Conference 2010]. <i>Deutsche Medizinische Wochenschrift</i> , 2010 , 135 Suppl 3, S102-14	0	1
222	Exercise intolerance in chronic heart failure: mechanisms and therapies. Part II. 2010 , 17, 643-8		44
221	Global cardiovascular reserve dysfunction in heart failure with preserved ejection fraction. <i>Journal of the American College of Cardiology</i> , 2010 , 56, 845-54	15.1	458
220	Guanylyl cyclase activator ataciguat improves vascular function and reduces platelet activation in heart failure. 2010 , 62, 432-8		26
219	The right heart and pulmonary circulation (III). The pulmonary circulation in heart failure. 2010 , 63, 334-45		8
218	Measurement of breathlessness in clinical trials in patients with chronic heart failure: the need for a standardized approach: a systematic review. <i>European Journal of Heart Failure</i> , 2010 , 12, 137-47	12.3	47
217	Pulmonary hypertension with left-sided heart disease. 2010 , 7, 648-59		101
216	Cardiopulmonary exercise testing in patients with pulmonary arterial hypertension: an evidence-based review. <i>Journal of Heart and Lung Transplantation</i> , 2010 , 29, 159-73	5.8	118
215	Ventilatory efficiency and dyspnea on exertion improvements are related to reduced pulmonary pressure in heart failure patients receiving Sildenafil. <i>International Journal of Cardiology</i> , 2010 , 144, 410-2	3.2	24
214	Sildenafil prevents mortality and reduces hippocampal damage after permanent, stepwise, 4-vessel occlusion in rats. 2010 , 81, 631-40		11
213	Pulmonary hypertension in heart failure. 2010 , 16, 461-74		63
212	La circulaci3n pulmonar en la insuficiencia cardiaca. 2010 , 63, 334-345		20
211	Heart failure and pulmonary hypertension. <i>Heart Failure Clinics</i> , 2010 , 6, 215-22	3.3	11
210	New insights for the diagnosis and management of right ventricular failure, from molecular imaging to targeted right ventricular therapy. 2010 , 25, 131-40		30

209	Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease. 2011 , 123, 2263-73		395
208	Invasive hemodynamic assessment in heart failure. 2011 , 29, 269-80		34
207	[Thoracic fluid content - a possible determinant of ventilatory efficiency in patients with heart failure]. 2011 , 30, 711-6		2
206	Thoracic fluid content is a possible determinant of ventilatory efficiency in patients with heart failure. 2011 , 30, 711-716		1
205	Phosphodiesterase type 5 inhibitors as adjunctive therapy in the management of systolic heart failure. 2011 , 45, 1551-8		11
204	Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment. <i>European Heart Journal</i> , 2011 , 32, 670-9	9.5	715
203	Molecular Basis of Pulmonary Hypertension in Left Heart Failure. 2011 , 259-271		
202	In patients with aortic stenosis increased flow-mediated dilation is independently associated with higher peak jet velocity and lower asymmetric dimethylarginine levels. 2011 , 161, 893-9		6
201	Current therapeutics and practical management strategies for pulmonary arterial hypertension. 2011 , 162, 201-13		37
200	Phosphodiesterases and cardiac cGMP: evolving roles and controversies. 2011 , 32, 360-5		73
199	Heart failure with preserved ejection fraction: pathophysiology and emerging therapies. 2011 , 29, e6-21		26
198	Pulmonary hypertension due to left heart disease: updated Recommendations of the Cologne Consensus Conference 2011. <i>International Journal of Cardiology</i> , 2011 , 154 Suppl 1, S34-44	3.2	21
197	Medical therapy for chronic heart failure. 2011 , 378, 713-21		64
196	Pulmonary hypertension related to left-sided cardiac pathology. 2011 , 2011, 381787		30
195	Emerging Strategies in the Treatment of Heart Failure. 2011 , 728-741		
194	Phosphodiesterase-5 inhibition mimics intermittent reoxygenation and improves cardioprotection in the hypoxic myocardium. <i>PLoS ONE</i> , 2011 , 6, e27910	3.7	20
193	PDE5 Inhibition With Sildenafil Improves Left Ventricular Diastolic Function, Cardiac Geometry, and Clinical Status in Patients With Stable Systolic Heart Failure: Results of a 1-Year, Prospective, Randomized, Placebo-Controlled Study. 2011 , 2011, 323-325		
192	Kein längeres Leben durch komplette Dissektion?. 2011 , 5, 21-22		1

191	Haemodynamic effects of long-term administration of sildenafil in normotensive pregnant and non-pregnant rats. 2011 , 118, 615-23		12
190	Pulmonary hypertension associated with left heart disease: characteristics, emerging concepts, and treatment strategies. 2011 , 54, 154-67		59
189	Pulmonary vasodilation in acute and chronic heart failure: empiricism and evidence. <i>Current Heart Failure Reports</i> , 2011 , 8, 219-25	2.8	2
188	Sildenafil preserves lung endothelial function and prevents pulmonary vascular remodeling in a rat model of diastolic heart failure. <i>Circulation: Heart Failure</i> , 2011 , 4, 198-206	7.6	44
187	Defining the phenotypes for pulmonary hypertension associated with diastolic heart failure. <i>Circulation: Heart Failure</i> , 2011 , 4, 238-40	7.6	7
186	Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study. 2011 , 124, 164-74		399
185	Res-erection of Viagra as a heart drug. <i>Circulation: Heart Failure</i> , 2011 , 4, 2-4	7.6	6
184	Pulmonary vascular response patterns during exercise in left ventricular systolic dysfunction predict exercise capacity and outcomes. <i>Circulation: Heart Failure</i> , 2011 , 4, 276-85	7.6	122
183	PDE5 inhibition with sildenafil improves left ventricular diastolic function, cardiac geometry, and clinical status in patients with stable systolic heart failure: results of a 1-year, prospective, randomized, placebo-controlled study. <i>Circulation: Heart Failure</i> , 2011 , 4, 8-17	7.6	298
182	Phosphodiesterase-5 Inhibition to Improve Clinical Status and Exercise Capacity in Diastolic Heart Failure (RELAX) trial: rationale and design. <i>Circulation: Heart Failure</i> , 2012 , 5, 653-9	7.6	98
181	Pulmonary hypertension and right ventricular failure in left ventricular systolic dysfunction. 2012 , 27, 262-72		13
180	Pathological cardiac hypertrophy alters intracellular targeting of phosphodiesterase type 5 from nitric oxide synthase-3 to natriuretic peptide signaling. 2012 , 126, 942-51		29
179	Phosphodiesterase 5 inhibition with sildenafil reverses exercise oscillatory breathing in chronic heart failure: a long-term cardiopulmonary exercise testing placebo-controlled study. <i>European Journal of Heart Failure</i> , 2012 , 14, 82-90	12.3	87
178	Chronic Inhibition of cGMP phosphodiesterase 5A improves diabetic cardiomyopathy: a randomized, controlled clinical trial using magnetic resonance imaging with myocardial tagging. 2012 , 125, 2323-33		129
177	Protein kinase G inhibits pressure overload-induced cardiac remodeling and is required for the cardioprotective effect of sildenafil in vivo. 2012 , 1, e003731		54
176	Pressure-overload-induced subcellular relocalization/oxidation of soluble guanylyl cyclase in the heart modulates enzyme stimulation. 2012 , 110, 295-303		55
175	Pulmonary hypertension in left heart disease. 2012 , 21, 338-46		50
174	Long-term effects of sildenafil in a rat model of chronic mitral regurgitation: benefits of ventricular remodeling and exercise capacity. 2012 , 125, 1390-401		51

173	Pulmonary Hypertension in Heart Failure With Preserved Ejection Fraction: A Target of Phosphodiesterase-5 Inhibition in a 1-Year Study. 2012 , 2012, 340-342		1
172	Pulmonary hypertension due to left heart disease. 2012 , 126, 975-90		294
171	Cardiac uses of phosphodiesterase-5 inhibitors. <i>Journal of the American College of Cardiology</i> , 2012 , 59, 9-15	15.1	65
170	Selective PDE5A inhibition with sildenafil rescues left ventricular dysfunction, inflammatory immune response and cardiac remodeling in angiotensin II-induced heart failure in vivo. <i>Basic Research in Cardiology</i> , 2012 , 107, 308	11.8	47
169	Nitric oxide modulation as a therapeutic strategy in heart failure. <i>Heart Failure Clinics</i> , 2012 , 8, 255-72	3.3	11
168	Right ventricular performance in chronic congestive heart failure. 2012 , 30, 271-82		4
167	Sildenafil improves microvascular O2 delivery-to-utilization matching and accelerates exercise O2 uptake kinetics in chronic heart failure. 2012 , 303, H1474-80		42
166	Pulmonary hypertension. 2012 , 308, 1366-74		57
165	Pulmonary hypertension in left heart disease: a review. <i>International Journal of Cardiology</i> , 2012 , 156, 253-8	3.2	7
164	Patch valvuloplasty in patients with posterior chordae rupture. <i>International Journal of Cardiology</i> , 2012 , 154, 206-7	3.2	6
163	Therapeutic potential of sildenafil in patients with heart failure and reactive pulmonary hypertension. <i>International Journal of Cardiology</i> , 2012 , 154, 205-6	3.2	20
162	Hemodynamic and clinical benefits associated with chronic sildenafil therapy in advanced heart failure: experience of the Montréal Heart Institute. 2012 , 28, 69-73		13
161	Endothelial dysfunction, arterial stiffness, and heart failure. <i>Journal of the American College of Cardiology</i> , 2012 , 60, 1455-69	15.1	292
160	World Health Organization Pulmonary Hypertension group 2: pulmonary hypertension due to left heart disease in the adult--a summary statement from the Pulmonary Hypertension Council of the International Society for Heart and Lung Transplantation. <i>Journal of Heart and Lung Transplantation</i> , 2012 , 31, 913-33	5.8	165
159	Effects of chronic sildenafil use on pulmonary hemodynamics and clinical outcomes in heart transplantation. <i>Journal of Heart and Lung Transplantation</i> , 2012 , 31, 1281-7	5.8	35
158	Cardiopulmonary exercise testing in adults with congenital heart disease. 2012 , 34, 47-52		7
157	Pulmonary hypertension associated with left-sided heart disease. <i>Heart Failure Clinics</i> , 2012 , 8, 447-59	3.3	24
156	Cardiac role of cyclic-GMP hydrolyzing phosphodiesterase type 5: from experimental models to clinical trials. <i>Current Heart Failure Reports</i> , 2012 , 9, 192-9	2.8	26

155	Right ventricular pulmonary hypertension. <i>Current Heart Failure Reports</i> , 2012 , 9, 303-8	2.8	4
154	Right side of heart failure. <i>Heart Failure Reviews</i> , 2012 , 17, 511-27	5	15
153	Treatment for pulmonary hypertension of left heart disease. 2012 , 14, 319-27		12
152	Phosphodiesterase inhibitors, congestive heart failure, and sudden death: time for re-evaluation. 2012 , 18, 229-33		13
151	Novel therapies in acute and chronic heart failure. 2012 , 135, 1-17		42
150	2013 ACCF/AHA Guideline for the Management of Heart Failure: Executive Summary. <i>Journal of the American College of Cardiology</i> , 2013 , 62, 1495-1539	15.1	233
149	Role of phosphodiesterase-5 inhibitors in heart failure: emerging data and concepts. <i>Current Heart Failure Reports</i> , 2013 , 10, 26-35	2.8	14
148	Medication management of chronic heart failure in older adults. 2013 , 30, 765-82		15
147	Pulmonary hypertension due to left heart diseases. <i>Journal of the American College of Cardiology</i> , 2013 , 62, D100-8	15.1	437
146	Management of pulmonary hypertension in left heart disease. 2013 , 7, 131-51		9
145	2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. 2013 , 128, e240-327		1927
144	New therapeutic options in heart failure. What's on the horizon? An overview. <i>International Journal of Cardiology</i> , 2013 , 170, 95-106	3.2	3
143	Pathophysiology of cardiorenal syndrome in decompensated heart failure: role of lung-right heart-kidney interaction. <i>International Journal of Cardiology</i> , 2013 , 169, 379-84	3.2	43
142	Left ventricular dysfunction with pulmonary hypertension: part 2: prognosis, noninvasive evaluation, treatment, and future research. <i>Circulation: Heart Failure</i> , 2013 , 6, 584-93	7.6	22
141	Acute effect of sildenafil on central hemodynamics in mechanically ventilated patients with WHO group III pulmonary hypertension and right ventricular failure necessitating administration of dobutamine. <i>International Journal of Cardiology</i> , 2013 , 167, 848-54	3.2	6
140	Ventilatory efficiency slope correlates with functional capacity, outcomes, and disease severity in pediatric patients with pulmonary hypertension. <i>International Journal of Cardiology</i> , 2013 , 169, 445-8	3.2	30
139	Phosphodiesterase type 5 inhibitors improve endothelial function and may benefit cardiovascular conditions. 2013 , 126, 192-9		25
138	2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. <i>Journal of the American College of Cardiology</i> , 2013 , 62, e147-239	15.1	4318

137	Pulmonary hypertension in patients undergoing cardiac surgery: pathophysiology, perioperative management, and outcomes. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2013 , 27, 551-72	2.1	25
136	Pulmonary hypertension associated with left heart disease. 2013 , 34, 665-80		11
135	The cGMP signaling pathway as a therapeutic target in heart failure with preserved ejection fraction. 2013 , 2, e000536		82
134	Pharmacologic Management of Heart Failure in the Ambulatory Setting. 2013 , 241-269		1
133	Sildenafil in Heart failure (SilHF). An investigator-initiated multinational randomized controlled clinical trial: rationale and design. <i>European Journal of Heart Failure</i> , 2013 , 15, 119-22	12.3	35
132	Audit of the aetiology and prevalence of pulmonary hypertension in a tertiary hospital setting. 2013 , 43, 323-7		1
131	Cardiac output response to exercise in relation to metabolic demand in heart failure with preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2013 , 15, 776-85	12.3	202
130	Is chronic sildenafil therapy safe and clinically beneficial in patients with systolic heart failure?. 2013 , 19, 99-103		18
129	Protein kinase G I and heart failure: Shifting focus from vascular unloading to direct myocardial antiremodeling effects. <i>Circulation: Heart Failure</i> , 2013 , 6, 1268-83	7.6	19
128	Sildenafil increases sympathetically mediated vascular tone in humans. 2013 , 26, 762-9		12
127	Exercise intolerance in heart failure: update on exercise parameters for diagnosis, prognosis and therapeutic interventions. 2013 , 68, 495-504		5
126	WHO ₂ in second?: A practical review of World Health Organization group 2 pulmonary hypertension. 2013 , 144, 638-650		36
125	Is chronic inhibition of phosphodiesterase type 5 cardioprotective and safe? A meta-analysis of randomized controlled trials. 2014 , 12, 185		58
124	Machines versus medication for biventricular heart failure: focus on the total artificial heart. 2014 , 10, 593-609		8
123	Pharmacologic therapy for erectile dysfunction and its interaction with the cardiovascular system. 2014 , 19, 53-64		17
122	Lung capillary injury and repair in left heart disease: a new target for therapy?. 2014 , 127, 65-76		17
121	Exercise capacity and paroxysmal atrial fibrillation in patients with hypertrophic cardiomyopathy. <i>Heart</i> , 2014 , 100, 624-30	5.1	29
120	Pulmonary hypertension in hypertensive patients: association with diastolic dysfunction and increased pulmonary vascular resistance. 2014 , 31, 442-8		5

119	Do patients undergoing MitraClip implantation require routine ICU admission?. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2014 , 28, 1479-83	2.1	14
118	Additional use of a phosphodiesterase 5 inhibitor in patients with pulmonary hypertension secondary to chronic systolic heart failure: a meta-analysis. <i>European Journal of Heart Failure</i> , 2014 , 16, 444-53	12.3	19
117	Sildenafil exposure and hemodynamic effect after Fontan surgery. 2014 , 15, 28-34		33
116	Response to pulmonary arterial hypertension drug therapies in patients with pulmonary arterial hypertension and cardiovascular risk factors. <i>Pulmonary Circulation</i> , 2014 , 4, 669-78	2.7	14
115	Discovery of 3-(4-hydroxybenzyl)-1-(thiophen-2-yl)chromeno[2,3-c]pyrrol-9(2H)-one as a phosphodiesterase-5 inhibitor and its complex crystal structure. 2014 , 89, 86-98		21
114	Abnormalities in cardiopulmonary exercise testing ventilatory parameters in heart failure: pathophysiology and clinical usefulness. <i>Current Heart Failure Reports</i> , 2014 , 11, 80-7	2.8	20
113	Pathophysiology and potential treatments of pulmonary hypertension due to systolic left heart failure. 2014 , 211, 314-33		12
112	PDE5 inhibitor sildenafil in the treatment of heart failure: a meta-analysis of randomized controlled trials. <i>International Journal of Cardiology</i> , 2014 , 172, 581-7	3.2	30
111	Interaction between pulmonary hypertension and diastolic dysfunction in an elderly heart failure population. 2014 , 20, 98-104		9
110	Pulmonary hypertension in heart failure preserved ejection fraction: prevalence, pathophysiology, and clinical perspectives. <i>Circulation: Heart Failure</i> , 2014 , 7, 367-77	7.6	75
109	Outcomes in World Health Organization group II pulmonary hypertension: mortality and readmission trends with systolic and preserved ejection fraction-induced pulmonary hypertension. 2014 , 20, 467-75		27
108	Mechanisms of exercise intolerance in heart failure with preserved ejection fraction. 2014 , 78, 20-32		74
107	Intensive Care in Cardiac Failure. 2014 , 503-519		
106	Sildenafil treatment attenuates ventricular remodeling in an experimental model of aortic regurgitation. 2015 , 4, 592		8
105	Pulmonary hypertension in potential heart transplant recipients: current treatment strategies. 2015 , 20, 570-6		6
104	Inflammation in Heart Failure with Preserved Ejection Fraction. 2015 , 3-18		3
103	Under pressure: pulmonary hypertension associated with left heart disease. 2015 , 24, 665-73		17
102	Therapeutic potential of sildenafil in patients with chronic heart failure after cardiac surgery. 2015 , 5, 1-8		

101	Use of pulmonary arterial hypertension-approved therapy in the treatment of non-group 1 pulmonary hypertension at US referral centers. <i>Pulmonary Circulation</i> , 2015 , 5, 356-63	2.7	32
100	Small molecule and peptide therapies for chronic heart failure: a patent review (2011 - 2014). 2015 , 25, 1175-90		4
99	Comparative effectiveness of sildenafil for pulmonary hypertension due to left heart disease with HFrEF. 2015 , 38, 829-39		11
98	Left ventricular vs. biventricular mechanical support: Decision making and strategies for avoidance of right heart failure after left ventricular assist device implantation. <i>International Journal of Cardiology</i> , 2015 , 198, 241-50	3.2	52
97	Dramatic improvement of clinical and hemodynamic parameters of a heart transplant candidate with sildenafil treatment. <i>International Journal of Cardiology</i> , 2015 , 185, 148-9	3.2	1
96	Pathophysiology and clinical relevance of pulmonary remodelling in pulmonary hypertension due to left heart diseases. 2015 , 31, 416-29		25
95	Effects of sildenafil on ventricular and vascular function in heart failure with preserved ejection fraction. <i>Circulation: Heart Failure</i> , 2015 , 8, 533-41	7.6	49
94	Impact of pharmacologic interventions--treating endothelial dysfunction and group 2 pulmonary hypertension. 2015 , 57, 473-9		7
93	The pathophysiology of pulmonary hypertension in left heart disease. 2015 , 309, L924-41		40
92	Molecular Screen Identifies Cardiac Myosin-Binding Protein-C as a Protein Kinase G- β Substrate. <i>Circulation: Heart Failure</i> , 2015 , 8, 1115-22	7.6	25
91	Therapeutic effects of udenafil on pressure-overload cardiac hypertrophy. 2015 , 38, 597-604		8
90	Management of Heart Failure. 2015 ,		1
89	Pulmonary hypertension in heart failure with preserved ejection fraction. <i>Journal of Heart and Lung Transplantation</i> , 2015 , 34, 273-81	5.8	15
88	The Right Ventricle in Health and Disease. <i>Respiratory Medicine</i> , 2015 ,	0.2	4
87	Defining the system: contributors to exercise limitations in heart failure. <i>Heart Failure Clinics</i> , 2015 , 11, 1-16	3.3	16
86	Targeting heart failure with preserved ejection fraction: current status and future prospects. 2016 , 12, 129-41		19
85	Group 2 PH: Medical Therapy. 2016 , 59, 71-7		3
84	Phosphodiesterase type-5 inhibitor use in type 2 diabetes is associated with a reduction in all-cause mortality. <i>Heart</i> , 2016 , 102, 1750-1756	5.1	58

83	Pulmonary Hypertension in the Era of Mechanical Circulatory Support. 2016 , 62, 505-12		8
82	Lung Capillary Stress Failure and Arteriolar Remodelling in Pulmonary Hypertension Associated with Left Heart Disease (Group 2 PH). 2016 , 59, 11-21		16
81	Impaired Right Ventricular-Pulmonary Arterial Coupling and Effect of Sildenafil in Heart Failure With Preserved Ejection Fraction: An Ancillary Analysis From the Phosphodiesterase-5 Inhibition to Improve Clinical Status And Exercise Capacity in Diastolic Heart Failure (RELAX) Trial. <i>Circulation: Heart Failure</i> , 2016 , 9, e002729	7.6	53
80	Present and future pharmacotherapeutic agents in heart failure: an evolving paradigm. <i>British Journal of Pharmacology</i> , 2016 , 173, 1911-24	8.6	13
79	Sildenafil in heart failure with reactive pulmonary hypertension (Sildenafil HF) clinical trial (rationale and design). <i>Pulmonary Circulation</i> , 2016 , 6, 161-7	2.7	6
78	[Pulmonary hypertension associated with left heart disease: recommendations of the Cologne Consensus Conference 2016]. <i>Deutsche Medizinische Wochenschrift</i> , 2016 , 141, S48-S56	0	5
77	Pulmonary Hypertension in Heart Failure Patients Presenting at OAUTHC, Ile-Ife, Nigeria. <i>Clinical Medicine Insights: Cardiology</i> , 2016 , 10, 187-193	3.2	
76	Lungenhochdruck bei Linksherzerkrankungen. <i>Wiener Klinisches Magazin: Beilage Zur Wiener Klinischen Wochenschrift</i> , 2016 , 19, 198-203	0	1
75	Update in treatment options in pulmonary hypertension. <i>Journal of Heart and Lung Transplantation</i> , 2016 , 35, 695-703	5.8	18
74	Everything you ever wanted to know about phosphodiesterase 5 inhibitors and the heart (but never dared ask): How do they work?. <i>Journal of Endocrinological Investigation</i> , 2016 , 39, 131-42	5.2	18
73	Is sildenafil neutral on cardiopulmonary performance in group 2 pulmonary hypertension? More details for interpretation. <i>European Journal of Heart Failure</i> , 2017 , 19, 691	12.3	2
72	The challenge of frailty and sarcopenia in heart failure with preserved ejection fraction. <i>Heart</i> , 2017 , 103, 184-189	5.1	33
71	Pulmonary hemodynamics and effects of phosphodiesterase type 5 inhibition in heart failure: a meta-analysis of randomized trials. <i>BMC Cardiovascular Disorders</i> , 2017 , 17, 150	2.3	23
70	Visceral Congestion in Heart Failure: Right Ventricular Dysfunction, Splanchnic Hemodynamics, and the Intestinal Microenvironment. <i>Current Heart Failure Reports</i> , 2017 , 14, 519-528	2.8	30
69	Phosphodiesterase-5 inhibitors as novel cardioprotective agents: have we reached threshold for large-scale clinical trials?. <i>Heart</i> , 2017 , 103, 1745	5.1	
68	Therapeutic benefits of phosphodiesterase-5 inhibition in chronic heart failure: A meta-analysis. <i>Interventional Medicine & Applied Science</i> , 2017 , 9, 123-135	0.7	2
67	Pulmonary hypertension due to left heart disease causes intrapulmonary venous arterialization in rats. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2017 , 154, 1742-1753.e8	1.5	9
66	Multiple Avenues of Modulating the Nitric Oxide Pathway in Heart Failure Clinical Trials. <i>Current Heart Failure Reports</i> , 2018 , 15, 44-52	2.8	9

65	Sildenafil for improving outcomes in patients with corrected valvular heart disease and persistent pulmonary hypertension: a multicenter, double-blind, randomized clinical trial. <i>European Heart Journal</i> , 2018 , 39, 1255-1264	9.5	105
64	Echocardiographic validation of pulmonary hypertension due to heart failure with reduced ejection fraction in mice. <i>Scientific Reports</i> , 2018 , 8, 1363	4.9	10
63	Will we be singing a different tune on combined post- and pre-capillary pulmonary hypertension?. <i>European Respiratory Journal</i> , 2018 , 51,	13.6	2
62	Intersection of Pulmonary Hypertension and Right Ventricular Dysfunction in Patients on Left Ventricular Assist Device Support: Is There a Role for Pulmonary Vasodilators?. <i>Circulation: Heart Failure</i> , 2018 , 11, e004255	7.6	17
61	Targeting phosphodiesterase 5 as a therapeutic option against myocardial ischaemia/reperfusion injury and for treating heart failure. <i>British Journal of Pharmacology</i> , 2018 , 175, 223-231	8.6	21
60	Pulmonary Hypertension Associated With Left-Sided Heart Disease. 2018 , 223-229		
59	Pulmonary hypertension-targeted therapies in heart failure: A systematic review and meta-analysis. <i>PLoS ONE</i> , 2018 , 13, e0204610	3.7	7
58	cGMP at the centre of attention: emerging strategies for activating the cardioprotective PKG pathway. <i>Basic Research in Cardiology</i> , 2018 , 113, 24	11.8	42
57	Haemodynamics, dyspnoea, and pulmonary reserve in heart failure with preserved ejection fraction. <i>European Heart Journal</i> , 2018 , 39, 2810-2821	9.5	88
56	Cardiovascular Safety of Phosphodiesterase Type 5 Inhibitors After Nearly 2 Decades on the Market. <i>Sexual Medicine Reviews</i> , 2018 , 6, 583-594	5.6	14
55	Pulmonary Hypertension and Heart Failure: A Dangerous Liaison. <i>Heart Failure Clinics</i> , 2018 , 14, 297-309	3.3	10
54	Phosphodiesterase-5 Inhibition Alleviates Pulmonary Hypertension and Basal Lamina Thickening in Rats Challenged by Chronic Hypoxia. <i>Frontiers in Physiology</i> , 2018 , 9, 289	4.6	5
53	Phosphodiesterase 2 inhibition preferentially promotes NO/guanylyl cyclase/cGMP signaling to reverse the development of heart failure. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018 , 115, E7428-E7437	11.5	24
52	Pulmonary hypertension associated with left heart disease: Updated Recommendations of the Cologne Consensus Conference 2018. <i>International Journal of Cardiology</i> , 2018 , 272S, 53-62	3.2	32
51	Pulmonary hypertension in HFpEF and HFrEF: Pathophysiology, diagnosis, treatment approaches. <i>Herz</i> , 2019 , 44, 483-490	2.6	9
50	Pulmonary Hypertension in Advanced Heart Failure: Assessment and Management of the Failing RV and LV. <i>Current Heart Failure Reports</i> , 2019 , 16, 119-129	2.8	2
49	Effects of PDE-5 Inhibition on the Cardiopulmonary System After 2 or 4 Weeks of Chronic Hypoxia. <i>Cardiovascular Drugs and Therapy</i> , 2019 , 33, 407-414	3.9	6
48	Challenges in pulmonary hypertension associated with left heart disease. <i>Expert Review of Cardiovascular Therapy</i> , 2019 , 17, 461-472	2.5	1

47	Sildenafil: Time to Look Beyond Pulmonary Pressures. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2019 , 33, 1657-1658	2.1	0
46	Phosphodiesterase 5 inhibitors for pulmonary hypertension. <i>The Cochrane Library</i> , 2019 , 1, CD012621	5.2	32
45	Effect of prolonged treatment with phosphodiesterase-5-inhibitors on endothelial dysfunction in vascular diseases and vascular risk conditions: A systematic review analysis and meta-analysis of randomized double-blind placebo-controlled trials. <i>International Journal of Clinical Practice</i> , 2019 , 73, e13296	2.9	4
44	Pulmonary hypertension in left heart disease. <i>Archives of Medical Science</i> , 2019 , 15, 262-273	2.9	14
43	Multiplicity of Nitric Oxide and Natriuretic Peptide Signaling in Heart Failure. <i>Journal of Cardiovascular Pharmacology</i> , 2020 , 75, 370-384	3.1	8
42	Targeted therapy with phosphodiesterase 5 inhibitors in patients with pulmonary hypertension due to heart failure and elevated pulmonary vascular resistance: a systematic review. <i>Pulmonary Circulation</i> , 2020 , 10, 2045894020948780	2.7	2
41	Factors Associated with Ineffectiveness of Sildenafil Treatment in Patients with End-Stage Heart Failure and Elevated Pulmonary Vascular Resistance. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	1
40	Peripheral endothelial dysfunction is a novel risk factor for systolic dysfunction and heart failure progression. <i>IJC Heart and Vasculature</i> , 2020 , 30, 100584	2.4	2
39	Pulmonary Hypertension Due to Left Heart Disease: Diagnosis, Pathophysiology, and Therapy. <i>Hypertension</i> , 2020 , 75, 1397-1408	8.5	21
38	Pulmonary vascular resistance as a potential marker of reactive pulmonary hypertension reduction following sildenafil therapy in patients disqualified from orthotopic heart transplantation. <i>Advances in Medical Sciences</i> , 2020 , 65, 298-303	2.8	
37	Cardiac Cyclic Nucleotide Phosphodiesterases: Roles and Therapeutic Potential in Heart Failure. <i>Cardiovascular Drugs and Therapy</i> , 2020 , 34, 401-417	3.9	7
36	Sildenafil beyond erectile dysfunction and pulmonary arterial hypertension: Thinking about new indications. <i>Fundamental and Clinical Pharmacology</i> , 2021 , 35, 235-259	3.1	7
35	Sacubitril-valsartan improves conduit vessel function and functional capacity and reduces inflammation in heart failure with reduced ejection fraction. <i>Journal of Applied Physiology</i> , 2021 , 130, 256-268	3.7	4
34	Pulmonary vasodilator use in continuous-flow left ventricular assist device management. <i>Annals of Translational Medicine</i> , 2021 , 9, 522	3.2	
33	CRD-733, a Novel PDE9 (Phosphodiesterase 9) Inhibitor, Reverses Pressure Overload-Induced Heart Failure. <i>Circulation: Heart Failure</i> , 2021 , 14, e007300	7.6	6
32	Heart Failure with Preserved Ejection Fraction. 2015 , 213-230		2
31	Modulation of cGMP in heart failure: a new therapeutic paradigm. <i>Handbook of Experimental Pharmacology</i> , 2009 , 485-506	3.2	44
30	[Phosphodiesterase-5 inhibitors for the treatment of pulmonary arterial hypertension]. <i>Archivos De Cardiologia De Mexico</i> , 2015 , 85, 215-24	0.2	6

29	Controversies in pulmonary hypertension due to left heart disease. <i>F1000prime Reports</i> , 2015 , 7, 07		13
28	Phosphodiesterase-5 Inhibitors Improve Clinical Outcomes, Exercise Capacity and Pulmonary Hemodynamics in Patients With Heart Failure With Reduced Left Ventricular Ejection Fraction: A Meta-Analysis. <i>Journal of Clinical Medicine Research</i> , 2017 , 9, 488-498	2.9	21
27	Pulmonary Hypertension in Heart Failure Patients. <i>Cardiac Failure Review</i> , 2020 , 6, e05	4.2	2
26	Asymptomatic Left Ventricle Systolic Dysfunction. <i>European Cardiology Review</i> , 2020 , 15, e13	3.9	9
25	Pulmonary hypertension: types and treatments. <i>Current Cardiology Reviews</i> , 2015 , 11, 73-9	2.4	22
24	Sildenafil is more selective pulmonary vasodilator than prostaglandin E1 in patients with pulmonary hypertension due to heart failure. <i>Physiological Research</i> , 2011 , 60, 303-8	2.1	4
23	Cardiac Effects of Phosphodiesterase-5 Inhibitors: Efficacy and Safety. <i>Cardiovascular Drugs and Therapy</i> , 2021 , 1	3.9	1
22	Medical Therapy for Heart Failure. 2010 , 29-68		
21	Heart Failure. 2010 , 1036-1053		
20	Right Ventricular Dysfunction in Pulmonary Hypertension. 2011 , 1313-1331		
19	Pulmonale Hypertonie. 2011 , 309-334		
18	Pulmonary hypertension secondary to left heart failure. 2011 , 425-434		
17	Combined phosphodiesterase inhibitors in end-stage heart failure: A case presentation. <i>World Journal of Cardiovascular Diseases</i> , 2013 , 03, 266-267	0	
16	Pulmonary Hypertension. 2014 , 378-393		
15	Pulmonary Hypertension in Congenital Heart Disease. 2014 , 2159-2199		
14	The Right Ventricle in Left Heart Failure. <i>Respiratory Medicine</i> , 2015 , 361-390	0.2	
13	Pulmonary Hypertension in Patients Without Pulmonary Arterial Hypertension. 2016 , 29-61		
12	Pulmonary Hypertension in Left Heart Disease. 2017 , 341-369		

11	OBSOLETE: Pulmonary Hypertension Associated with Left-Sided Heart Disease. 2018 ,		
10	[Problematic aspects of pulmonary hypertension due to left heart disease: focus on combined postcapillary and precapillary pulmonary hypertension]. <i>Terapevticheskii Arkhiv</i> , 2020 , 92, 54-62	0.9	2
9	Cardiac contractility modulation in patients with heart failure refractory to drug treatment. <i>Experimental and Clinical Cardiology</i> , 2011 , 16, 43-6		3
8	Molekulare Prinzipien in der Kardiologie: Die Basis für zukünftige Behandlungsansätze.		
7	Effects of sildenafil on symptoms and exercise capacity for heart failure with reduced ejection fraction and pulmonary hypertension (The SilHF study): A randomised placebo-controlled multicentre trial. <i>European Journal of Heart Failure</i> ,	12.3	1
6	Combined pre- and post-capillary pulmonary hypertension in left heart disease. <i>Heart Failure Reviews</i> ,	5	2
5	Sex-specific effects of daily tadalafil on diabetic heart kinetics in RECOGITO, a randomized, double-blind, placebo-controlled trial. <i>Science Translational Medicine</i> , 2022 , 14,	17.5	1
4	Heart Failure with Preserved Ejection Fraction and Pulmonary Hypertension: Focus on Phosphodiesterase Inhibitors. 2022 , 15, 1024		
3	Investigation of Genes and Proteins Expression Associating Serotonin Signaling Pathway in Lung and Pulmonary Artery Tissues of Dogs with Pulmonary Hypertension Secondary to Degenerative Mitral Valve Disease: The Preliminary Study. 2022 , 9, 530		0
2	Cyclic nucleotide phosphodiesterases as therapeutic targets in cardiac hypertrophy and heart failure.		1
1	Phosphodiesterase Type 5 Inhibitors and Oral Nitrates in Male Patients with Ischemic Heart Disease.		0